BioCorRx EBIT

The latest EBIT for BICX is $-3.3M as of June 2026. That compares with $-4.3M in the prior-year period — up 23.9% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside BioCorRx's historical trend and sector peers before judging valuation or financial health.

Over the past year, BICX's EBIT moved from $-4.3M to $-3.3M — a 23.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioCorRx's operating scale or balance-sheet position.

Against its sector companies, BICX currently prints $-3.3M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at BioCorRx's growth, margins, and balance sheet.

A EBIT figure of $-3.3M for BICX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting BICX's EBIT ($-3.3M), review year-over-year change from $-4.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.